Recent Quotes (30 days)

You have no recent quotes
chg | %

Immunotech Laboratories Inc  

(Public, OTCMKTS:IMMB)   Watch this stock  
Find more results forPINK:IMMB
0.00000 (0.00%)
Oct 18 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 57,500.00
P/E     -
Div/yield     -
EPS -221.70
Shares 574.96M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '06) 2005
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -187.88% -134384.00%
Return on average equity - -
Employees 4 -
CDP Score - -


120 W Pomona Ave
MONROVIA, CA 91016-4557
United States - Map
+1-626-5384779 (Phone)
+1-818-4098988 (Fax)

Website links


Immunotech Laboratories, Inc. is a drug development company. The Company offers a drug platform, Irreversible Pepsin Fraction (IPF), which is a technology that can be used to facilitate a range of applications. Its flagship compound Immune Therapeutic Vaccine-1 (ITV-1) is a suspension of IPF, which is used in the treatment of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and Hepatitis C viruses and to modulate the immune system. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. The IPF modulates helper T1 cells expression of elaborate cytokines interferon (INF)-gamma, interleukin-2 (IL-2), which selectively promotes cell-mediated immune response and subsequently stimulates cytotoxic lymphocytes. The Company's other compounds in its pipeline include ITV-2 prenatal, ITV-3 Pediatric and ITV-4 HIV Vaccine.

Officers and directors

Harry H. Zhabilov Vice Chairman of the Board, Chief Science Officer
Age: 45
Roscoe M. Moore Jr. Ph.D. Director
Age: 70